JP2002332234A5 - - Google Patents

Download PDF

Info

Publication number
JP2002332234A5
JP2002332234A5 JP2002088076A JP2002088076A JP2002332234A5 JP 2002332234 A5 JP2002332234 A5 JP 2002332234A5 JP 2002088076 A JP2002088076 A JP 2002088076A JP 2002088076 A JP2002088076 A JP 2002088076A JP 2002332234 A5 JP2002332234 A5 JP 2002332234A5
Authority
JP
Japan
Prior art keywords
formula
formulation
voriconazole
present
cyclodextrin derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002088076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002332234A (ja
JP5089004B2 (ja
Filing date
Publication date
Priority claimed from GBGB9713149.4A external-priority patent/GB9713149D0/en
Application filed filed Critical
Publication of JP2002332234A publication Critical patent/JP2002332234A/ja
Publication of JP2002332234A5 publication Critical patent/JP2002332234A5/ja
Application granted granted Critical
Publication of JP5089004B2 publication Critical patent/JP5089004B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002088076A 1997-06-21 2002-03-27 ボリコナゾールを含有する薬剤製剤 Expired - Lifetime JP5089004B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations
GB9713149.4 1997-06-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP11503686A Division JP2000513029A (ja) 1997-06-21 1998-06-02 ボリコナゾールを含有する薬剤製剤

Publications (3)

Publication Number Publication Date
JP2002332234A JP2002332234A (ja) 2002-11-22
JP2002332234A5 true JP2002332234A5 (enExample) 2008-05-22
JP5089004B2 JP5089004B2 (ja) 2012-12-05

Family

ID=10814734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP11503686A Withdrawn JP2000513029A (ja) 1997-06-21 1998-06-02 ボリコナゾールを含有する薬剤製剤
JP2002088076A Expired - Lifetime JP5089004B2 (ja) 1997-06-21 2002-03-27 ボリコナゾールを含有する薬剤製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP11503686A Withdrawn JP2000513029A (ja) 1997-06-21 1998-06-02 ボリコナゾールを含有する薬剤製剤

Country Status (47)

Country Link
US (1) US6632803B1 (enExample)
EP (1) EP1001813B8 (enExample)
JP (2) JP2000513029A (enExample)
KR (1) KR100372988B1 (enExample)
CN (1) CN1125653C (enExample)
AP (1) AP912A (enExample)
AR (1) AR015900A1 (enExample)
AT (1) ATE238812T1 (enExample)
AU (1) AU724799B2 (enExample)
BG (1) BG64584B1 (enExample)
BR (1) BRPI9809468B8 (enExample)
CA (1) CA2295035C (enExample)
CO (1) CO4940450A1 (enExample)
CZ (1) CZ289570B6 (enExample)
DE (1) DE69814091T2 (enExample)
DK (1) DK1001813T3 (enExample)
DZ (1) DZ2523A1 (enExample)
EA (1) EA001924B1 (enExample)
EG (1) EG23910A (enExample)
ES (1) ES2195355T3 (enExample)
GB (1) GB9713149D0 (enExample)
HR (1) HRP980341B1 (enExample)
HU (1) HU228338B1 (enExample)
ID (1) ID22939A (enExample)
IL (1) IL132918A (enExample)
IS (1) IS2004B (enExample)
MA (1) MA26508A1 (enExample)
ME (1) ME00907B (enExample)
MY (1) MY118151A (enExample)
NO (1) NO313125B1 (enExample)
NZ (1) NZ501066A (enExample)
OA (1) OA11232A (enExample)
PA (1) PA8453201A1 (enExample)
PE (1) PE84899A1 (enExample)
PL (1) PL191295B1 (enExample)
PT (1) PT1001813E (enExample)
RS (1) RS49633B (enExample)
SA (1) SA98190159B1 (enExample)
SI (1) SI1001813T1 (enExample)
SK (1) SK282946B6 (enExample)
TN (1) TNSN98090A1 (enExample)
TR (1) TR199903191T2 (enExample)
TW (1) TW406023B (enExample)
UA (1) UA57083C2 (enExample)
UY (1) UY25055A1 (enExample)
WO (1) WO1998058677A1 (enExample)
ZA (1) ZA985364B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
JP4729306B2 (ja) * 2002-08-20 2011-07-20 ブリストル−マイヤーズ スクイブ カンパニー アリピプラゾール錯体の製剤と方法
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
EP2803357B1 (en) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达(北京)医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US20110224232A1 (en) * 2008-05-06 2011-09-15 Board Of Regents, The University Of Texas System Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
MX2010013363A (es) * 2008-06-06 2011-03-03 Glenmark Pharmaceuticals Ltd Formulacion topica estable contiene voriconazol.
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
EA201270283A1 (ru) 2009-08-19 2012-12-28 Рациофарм Гмбх Способ получения соэвапоратов и комплексы, содержащие вориконазол и циклодекстрин
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
CN107049935A (zh) 2010-06-29 2017-08-18 默沙东公司 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂
EP2409699B1 (en) * 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
WO2012171561A1 (en) 2011-06-15 2012-12-20 Synthon Bv Stabilized voriconazole composition
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
WO2013103924A2 (en) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
EP2662094B1 (en) 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
CA2872958A1 (en) 2012-05-11 2013-11-14 Cipla Limited Pharmaceutical composition
BR112015016331B1 (pt) 2013-01-11 2020-05-12 Xellia Pharmaceuticals Aps Formulação farmacêutica estabilizada e método de estabilização de uma composição compreendendo voriconazol
EP2968595A2 (en) 2013-03-14 2016-01-20 Fresenius Kabi USA LLC Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术(石家庄)有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物,其製備方法及作為抗微生物醫藥組合物之用途
EP3584245A4 (en) * 2017-02-17 2020-08-26 Wuhan LL Science And Technology Development Co., Ltd. TRIAZOLE ANTIBACTERIAL DERIVATIVE, ASSOCIATED PHARMACEUTICAL COMPOSITION AND USE
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP2002332234A5 (enExample)
JP2003531118A5 (enExample)
JP2006526031A5 (enExample)
JP2005518413A5 (enExample)
JP2007503202A5 (enExample)
JP2005508905A5 (enExample)
JP2007510619A5 (enExample)
JP2006515626A5 (enExample)
JP2002541233A5 (enExample)
JP2002543183A5 (enExample)
JP2006514012A5 (enExample)
JP2002533472A5 (enExample)
CA2349142A1 (en) Compositions and methods for stimulating gastrointestinal motility
JP2005511697A5 (enExample)
JP2002527396A5 (enExample)
JP2002510633A5 (enExample)
JP2003509349A5 (enExample)
JP2009500423A5 (enExample)
JP2002506864A5 (enExample)
JP2003503449A5 (enExample)
JP2002525323A5 (enExample)
JPH10287651A5 (enExample)
JP2008513510A5 (enExample)
JP2000159790A5 (enExample)
JP2008520662A5 (enExample)